HIV Medicine

Article	Citations
	174
Issue Information	97
	89
	80
Fostemsavir and ethinyl estradiol drug interaction: Clinical recommendations for co‐administration	55
Issue Information	51
HIV testing in primary care in a low‐prevalence area of Northeast England	49
Perspectives of people with HIV and HIV clinicians on characteristics of antiretroviral treatment and HIV‐related symptoms	46
Aetiology of fever of unknown origin in people living with HIV : A systematic review and meta‐analysis	44
Cellular and humoral response after mRNA SARS‐CoV‐2 vaccination in kidney transplant recipients living with HIV: A cross‐sectional study	42
	36
Subclinical atherosclerosis as detected by carotid ultrasound and associations with cardiac and HIV‐specific risk factors; the Archi‐Prevaleat project	33
Areas with high HIV prevalence: A spatial analysis of nationwide claims data in Germany	31
HIV cure: Are we going to make history?	30
Loneliness and social isolation in people with HIV aged ≥50 years. The No One Alone (NOA)‐GeSIDA study conducted by the GeSIDA 12021 study group	29
User‐reported outcomes of long‐acting injectable PrEP with Cabotegravir: Real‐world experience from Milan	25
Potentially inappropriate prescriptions and potential prescription omissions in older people living with HIV	24
Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy	24
Telemedicine in HIV health care during the COVID‐19 pandemic: An implementation research study in Buenos Aires, Argentina	24
Usable access to HIV testing and care among people with migrant backgrounds in Japan: A systematic review	23
Effects of transition from paediatric to adult HIV care on virological outcomes in sub‐Saharan Africa: A systematic review and meta‐analysis	22
HIV ‐1 viral load and reservoir size remain stable following SARS ‐ CoV	21
Disparities in HIV continuum of care in the paediatric population: A real‐life study in Brazil	21
Clinical characteristics of monkeypox virus infections among men with and without HIV: A large outbreak cohort in Germany	20
	20

Issue Information	19
	19
Issue Information	18
Assessment of targeted intervention programme under the National AIDS Control Program among men who have sex with men in India	18
Using an automated decision support tool to improve HIV prescribing: A feasibility study	18
Oral Abstracts	17
Issue Information	17
No increased risk of tuberculosis‐related immune reconstitution inflammatory syndrome with integrase inhibitor‐based antiretroviral therapy in people withHIV with profound immunosuppression	16
Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV‐1 in need of parenteral antiretroviral therapy	16
Changing prevalence and risk factors for Toxoplasma gondii seropositivity and disease in persons with HIV	16
Dual drivers of polypharmacy in people with HIV : Quantifying the independent associations of aging and long‐term antiretroviral therapy	16
Exploring implementation considerations forgeriatric‐HIVclinics: A secondary analysis from a scoping review onHIVmodels of geriatric care	16
Associations between HIV infection and frailty status and its individual components: Are frailty components disproportionally affected?	16
The value of herpes zoster prevention in people aging with HIV: A narrative review	15
Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real‐world setting in Belgium	15
The first AI‐based Chatbot to promote HIV self‐management: A mixed methods usability study	15
Exploring the cascade of mental healthcare among people with HIV experiencing depressive symptoms in the UK and Ireland: The POPPY study	15
Efficacy and safety of dolutegravir/rilpivirine in real‐world clinical practice. GeSIDA study 1119	14
Effectiveness and tolerability of dolutegravir/lamivudine in virologically suppressed people with HIV at 96 weeks in a multicentre cohort	14
Issue Information	13
	13
Issue Information	13
The effect of HIV and mpox co‐infection on clinical outcomes: Systematic review and meta‐analysis	13
Influence of physical activity on endothelial function in people living with HIV	13
	13
British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of non‐tuberculous mycobacteria 2024	13
Gender equality in leadership of HIV care cascade clinical trials: A methodological study	12
Response to letter by Kumar et al. on “Exploring the cascade of mental health care among people with HIV experiencing depressive symptoms in the UK and Ireland: The POPPY	12
AI in medicine: No longer the future, but the present	11
	11
Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real‐world cohort analysis	11
“Editorial comment on: Increased incidence of diabetes in people living with HIV treated with first‐line integrase strand transfer inhibitors: A French multicentre retrospective study”	11
Access to care and impact on HIV treatment interruptions during the COVID‐19 pandemic among people living with HIV in British Columbia	10
Long‐acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re‐suppression outcomes in virally suppressed individual	10
	10
	10
Temporal network analysis of comorbidities among people with HIV in South Carolina	10
Viral rebound on antiretroviral therapy in France according to region of origin, sex, and HIV acquisition group. Results from the French Hospital Database on HIV (ANRS CO4	10
Index	10
Stigma, depression and pillbox return among adults living with HIV in rural Tanzania: A prospective cohort study	10
Increasing HIV early diagnosis by implementing an automated screening strategy in emergency departments	10
	10
Blood pressure and metabolic outcomes after efavirenz‐ or dolutegravir‐based therapy started in acute HIV infection	10
Clinical significance and management of low‐level HIV viremia in the era of integrase strand transfer inhibitors	9
Frequent hepatitis B surface antigen ( HBsAg) clearance during tenofovir therapy in persons with HIV	9
Predictors of poor health‐related quality of life among people living with HIV aged ≥60 years in the PISCIS cohort: Findings from the Vive+ project	9
Association between markers of hepatitis B virus infection and risk of virological rebound in people with HIV receiving antiretroviral therapy	9
The role of HIV as a risk modifier for coronary endothelial function in young adults	9
Polypharmacy in HIV : Rethinking what counts and why it matters	9
Long‐acting cabotegravir and rilpivirine in people with HIV and obesity: Real‐world outcomes from the RELATIVITY	9

An updated systematic review of HIV‐associated cryptococcal meningitis treatment strategies	9
HCV incidence in people with HIV in southwest China: A retrospective cohort study (2004–2023)	9
Towards inclusive HIV cure development: Identifying important and acceptable HIV cure attributes a	9
De‐simplifying antiretroviral therapy from a single‐tablet to a two‐tablet regimen: Acceptance, patient‐reported outcomes, and cost savings in a multicentre study	9
Oral Abstracts	9
Highlights from the 20th European AIDS Conference: 15–18 October 2025, Paris, France	8
Cardiovascular risk knowledge stratified by predicted cardiovascular risk level among people living with HIV attending a tertiary	8
Sex differences in cardiovascular disease and associated factors in people living with HIV : Evidence from All of Us program	8
Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with human immunodeficiency virus‐1 (HIV‐1): A systematic literature rev	8
History of sexually transmitted infections among mpox cases in the 2022 outbreak in Spain	8
Increased incidence of diabetes in people living with HIV treated with first‐line integrase strand transfer inhibitors: A French multicentre retrospective study	8
Burden of liver steatosis and liver fibrosis in a large cohort of people living with HIV	8
Virtual care pathways for people living with HIV: A mixed‐methods systematic review	8
Knowledge and HIV‐related stigma among Portuguese healthcare professionals: A cross‐sectional analysis	8
Frailty and frailty screening: A qualitative study to elicit perspectives of people living with HIV and their healthcare professionals	8
Point‐of‐care nucleic acid testing – a step forward in controlling the HIV epidemic: A review	8
“Real world” efficacy of bulevirtide in HBV/HDV‐related cirrhosis including people living with HIV: Results from the compassionate use programme at INMI Spa	8
Y181C ‐associated virologic failure during long‐acting injectable cabotegravir/Rilpivirine in a patient engaged in intensive intravenous Chemsex	8
Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir‐based dual therapy. Bi‐lipid study	8
Effectiveness of switching regimen in people living with HIV and persistent low‐level viraemia in the modern antiretroviral treatment era	8
Late diagnosis of human immunodeficiency virus ( HIV ) and its associated factors in Asian countries: A systematic review	8
Supporting long‐term engagement in HIV clinical care: Learning from the COVID ‐19 pandemic	8
Issue Information	8
Immunostimulatory effects of Hsp70 fragments and Hsp27 in design of novel HIV‐1 vaccine formulations	8
Clinical management of detectable viraemia during CAB / RPV long‐acting therapy: Are really	7
Availability and stock‐outs of paediatric antiretroviral treatment formulations at health facilities in Kenya and Uganda	7
Scars are frequently found as late sequelae in individuals affected by the 2022 mpox outbreak	7
Spatial and temporal trends in HIV / AIDS burden among South Asian countries from 1990 to 2021: A	7
Issue Information	7
CROI 2024 BHIVA working group summary	7
Quality of life among people living with HIV aged 50 years and over in Australia: Identifying opportunities to support better ageing	7
Biomarkers of inflammation and coagulation predict non‐AIDS‐defining events in a prospective cohort of virologically suppressed people living with HIV	7
Impact of the COVID ‐19 pandemic on missed opportunities for diagnosis of HIV infection:	7
Incidence and predictors of attrition from HIV treatment among adults living with HIV in high‐caseload facilities following implementation of universal test and treat strategy in	7
Examination of factors associated with mental health of people living with HIV in Kazakhstan: A cross‐sectional study based on the two‐continua model	7
Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA	7
Issue Information	7
	7
Anticholinergic medications associated with falls and frailty in people with HIV	7
Pneumocystis jirovecii pneumonia–Immune reconstitution inflammatory syndrome: A review of published cases	7
Author Index	7
Immune response to ART initiation in advanced HIV infection	7
The effect of Biktarvy (B/F/ TAF ) on whole‐body insulin sensitivity, lipid and endocrine profile in healthy volunteers	7
Late diagnosis of HIV: An updated consensus definition	7
Issue Information	7
Prevalence of, risk factors for, and target organ damage from metabolic syndrome among people living with HIV on ART: A cross‐sectional analysis in Chongqing, China	7
Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI‐net)	6
Sexual dysfunction care needs of gay, bisexual, and other men who have sex with men living with HIV in Montreal, Canada	6
Strategies to achieve the UNAIDS 95% HIV diagnosis target in Australia: Insights from a multidisciplinary roundtable	6
Implementation of frailty screening for older people living with HIV in Brighton, UK	6
Treatment durability, satisfaction and quality of life in virologically suppressed HIV ‐1 people switching to doravirine: Results from the French stu	6
Factors influencing the quality of life and social skills of children living with HIV: A case–control study	6
Cervical intraepithelial neoplasia progression and regression among women living with HIV in Zambia	6
Issue Information	6
Lipid nanoparticles in antiretroviral therapy: A nanotechnology breakthrough for HIV/AIDS treatment	6
‘We want it all’:ARTpreferences assessed byDesirability ofOutcomeRanking	6
Assessing weight change in adolescents and young adults with perinatally acquired HIV and integrase inhibitor use	6
Implementing the National Vaccination Plan in people with HIV in Italy	6
Worldwide changes in HIV ‐related stigma among people living with HIV : A cross‐temporal meta‐anal	6
Real‐world efficacy of bictegravir/emtricitabine/tenofovir alafenamide regimen in patients infected with HIV‐1 sub‐subtype A6 harbouring the L74I mutation	6
Awareness and early implementation of the European AIDS Clinical Society Guidance on statin use in HIV	6
	6
Sleep deficiency among people living with human immunodeficiency virus: A growing challenge	6
SARS‐CoV‐2 vaccine immunogenicity for people living with HIV: A systematic review and meta‐analysis	6
Intergenerational sex and early sexual debut are associated with HIV infection among transgender women in Paraguay	6
CHildren of the Cohort Study ( CHOC ): Exploring parenting desire among people living with HI	6
A cross‐sectional comparison of the use of frailty assessment tools in older people living with HIV	6
Issue Information	6
One for all, all for one: neuro‐HIV multidisciplinary platform for the assessment and management of neurocognitive complaints in people living with HIV	6
	6
Issue Information	6
Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin‐based regimen: A retrospective observational case series	5
Low‐level HIV viraemia during antiretroviral therapy: Longitudinal patterns and predictors of viral suppression	5
Cost of non‐communicable diseases in people living with HIV in the Central Denmark Region	5
Trends in preterm birth in women living with HIV in Switzerland over the last three decades: A multicentric, prospective, cohort study	5
Impact of the COVID‐19 pandemic on the HIV care continuum and associated factors in middle‐income countries: A mixed‐methods systematic review	5
	5
Hypertriglyceridaemia and gender differences in the risk of major adverse cardiovascular events in people with HIV : A single‐centre retrospective lo	5
Potential drug–drug interactions in males living with HIV who use drugs to treat lower urinary tract symptoms	5
Issue Information	5

Issue Information	5
Issue Information	5
Correction to ‘Abstracts of the 19th European AIDS Conference (# EACS2023 ), October 18–21, 2023,	5
Natural occurrence of drug resistance mutations to the HIV ‐1 capsid inhibitor lenacapavir	5
What are the predictors of change in multimorbidity among people with HIV? A longitudinal observational cohort study	5
Individual characteristics and time‐updated factors associated with antiretroviral treatment interruptions among people living with HIV in British Co	5
Colorectal cancer screening uptake and lesion detection in people living with HIV : A systematic review and meta‐analysis	5
	5
The outcomes of anxiety and depression symptom screening in a population with HIV : Insights from an HIV	5
	5
Impact of HBV serological status on HIV virological efficacy of two‐drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with	5
Issue Information	5
	5
	5
An overview of consent requirements for HIV and viral hepatitis B and C testing in Europe	5
	5
Factors associated with uptake of gynaecological care and cervical cancer screening among women in the Swiss HIV Cohort Study	5
Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real‐world insights from BICSTaR cohorts	5
Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III stud	5
Risk factors, management, and HPV genotyping of vulvar intraepithelial neoplasia ( VIN ) in women	5
Perceived disabling physical pain and suicidal ideation in aging people living with HIV cured of hepatitis C	5
Issue Information	5
Optimizing statin prescriptions for people living with HIV: Evidence for improved communication and shared care between primary care and specialist HIV	5
Comorbidities, comedications and potential drug–drug interactions among people living with HIV in China	5
Recognizing International Women's Day 2026	5
	5
	5
Sexually transmitted and blood‐borne infection risk reduction with methadone and buprenorphine/naloxone among people with prescription‐type opioid use disorder: Findings from a Canadian pragmatic rand	5
The impact of accumulating immune adaptation in circulating strains of HIV ‐1	5
Molecular epidemiological analysis and investigation of antiretroviral drug resistance profile, including capsid inhibitors, among treatment‐naïve individuals with HIV	4
Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real‐life experience from a French cohort (2019–2023)	4
Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV ‐suppressed individuals: 48 weeks and beyond	4
Cytomegalovirus infection among people living with HIV in Sweden: Case profiles, treatment strategies and patient outcomes at Karolinska University Hospital 2010–2020	4
Rapid HIV pre‐exposure prophylaxis (PrEP) initiation is safe and feasible: Experience from Wroclaw All Saints cohort in Poland 2017–2021	4
Taxonomic and functional profile of the anorectal microbiota in HIV‐positive and HIV‐negative men who have sex with men, using a metagenomic approach	4
No evidence of asymptomatic monkeypox infection in a highly sexually active MSM population in Austria	4
Severe ocular Mpox in person living with advanced HIV treated with extended course of tecovirimat	4
HIV treatment strategies across Central, Eastern and Southeastern Europe: New times, old problems	4
Long‐term immune reconstitution patterns and influencing factors in people living with HIV exhibiting suboptimal immune response after 24 months of a	4
Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025	4
Examining pathways between stigma, extreme weather exposure, resource insecurities and ART adherence among young men who have sex with men and female	4
Frailty in people 50 years or older living with HIV: A sex perspective	4
Issue Information	4
	4
	4
Clinical outcomes of long‐acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real‐world data from the Spanish	4
Rate of response to initial antiretroviral therapy according to level of pre‐existing HIV‐1 drug resistance detected by next‐generation sequencing in the strategic timing of antiretroviral treatment (	4
Real‐world experience with weight gain among pregnant women living with HIV who are using integrase inhibitors	4
Scaling HIV self‐testing to improve health equity among cisgender gay, bisexual and other men who have sex with men, trans and gender‐diverse people	4
Asian participants' experience in phase 3/3b studies of long‐acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96	4
Issue Information	4
Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV	4
Switch to a raltegravir‐based antiretroviral regimen in people with HIV and non‐alcoholic fatty liver disease: A randomized controlled trial	4
HIV and fracture: Risk, assessment and intervention	4
	4
PrEP for women in Europe: a systematic literature review	4
Strategies for strengthening same‐day ART initiation, tracing people living with HIV lost to follow‐up and viral load monitoring mechanisms in Ethiopia	4
Issue Information	4
Authors' Reply to Letter to the Editor Regarding ‘Effectiveness, safety, and patient‐reported outcomes of emtricitabine/tenofovir alafenamide‐based regimens for the treatment of HIV‐1 infection: Final	4
Advanced HIV disease: A review of diagnostic and prophylactic strategies	4
People diagnosed with HIV before continuing care in England are extremely unlikely to pass on HIV	4
EACS Abstract 2025	4
Late diagnosis of HIV in 2022: Why so little change?	4
Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies	4